Literature DB >> 9022895

Evaluation of a new, rapid and automated immunochemiluminometric assay for the measurement of serum intact parathyroid hormone.

V P Michelangeli1, P Heyma, P G Colman, P R Ebeling.   

Abstract

The Immulite parathyroid hormone (PTH) immunochemiluminometric assay (ICMA) was evaluated by measuring serum PTH concentrations in 134 volunteers and 25 patients with various diseases affecting bone and mineral metabolism and comparing with those measured by the Nichols Allegro immunoradiometric (IRMA) assay. Although the assays were highly correlated (r = 0.99. P < 0.0001), there were discrepancies at lower PTH concentrations which may be explained by the lower limit of detection of the ICMA assay. The anti-coagulants EDTA and heparin appeared to have significant effects on PTH measurement particularly at lower concentrations. Sera assayed by ICMA diluted out more uniformly than in the IRMA and there was no cross reactivity with parathyroid hormone-related peptide in either the IRMA or ICMA. Delays of up to 8 h in specimen handling did not appear to affect PTH measurements. The enhanced sensitivity of the Immulite ICMA intact PTH assay confers an advantage in the diagnosis of both hyper- and hypocalcaemia, while the shorter incubation times, automation and lack of radioactivity are important practical advantages.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9022895     DOI: 10.1177/000456329703400115

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  9 in total

Review 1.  Lessons from second- and third-generation parathyroid hormone assays in primary hyperparathyroidism.

Authors:  J C Souberbielle; P Boudou; C Cormier
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

2.  PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism.

Authors:  Mishaela R Rubin; David W Dempster; James Sliney; Hua Zhou; Thomas L Nickolas; Emily M Stein; Elzbieta Dworakowski; Maryann Dellabadia; Rebecca Ives; Donald J McMahon; Chiyuan Zhang; Shonni J Silverberg; Elizabeth Shane; Serge Cremers; John P Bilezikian
Journal:  J Bone Miner Res       Date:  2011-11       Impact factor: 6.741

3.  Direct, minimally invasive adenomectomy for primary hyperparathyroidism: An alternative to conventional neck exploration?

Authors:  P C Smit; I H Borel Rinkes; A van Dalen; T J van Vroonhoven
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

4.  The 25(OH)D/PTH threshold in black women.

Authors:  John F Aloia; Ding-Geng Chen; Henian Chen
Journal:  J Clin Endocrinol Metab       Date:  2010-08-04       Impact factor: 5.958

5.  Reference range for serum parathyroid hormone.

Authors:  John F Aloia; Martin Feuerman; James K Yeh
Journal:  Endocr Pract       Date:  2006 Mar-Apr       Impact factor: 3.443

6.  Therapy of hypoparathyroidism with intact parathyroid hormone.

Authors:  M R Rubin; J Sliney; D J McMahon; S J Silverberg; J P Bilezikian
Journal:  Osteoporos Int       Date:  2010-01-22       Impact factor: 4.507

7.  Dynamic and structural properties of the skeleton in hypoparathyroidism.

Authors:  Mishaela R Rubin; David W Dempster; Hua Zhou; Elizabeth Shane; Thomas Nickolas; James Sliney; Shonni J Silverberg; John P Bilezikian
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

8.  Comparison between Second- and Third-Generation PTH Assays during Minimally Invasive Parathyroidectomy (MIP).

Authors:  Marie-Hélène Gannagé-Yared; Nada Younès; Anne-Sophie Azzi; Ghassan Sleilaty
Journal:  Int J Endocrinol       Date:  2020-03-16       Impact factor: 3.257

9.  Chemical Characterization and Quantification of Circulating Intact PTH and PTH Fragments by High-Resolution Mass Spectrometry in Chronic Renal Failure.

Authors:  Kittrawee Kritmetapak; Louis A Losbanos; Jolaine M Hines; Katherine L O'Grady; Candice Z Ulmer; Hubert W Vesper; Felicity T Enders; Ravinder J Singh; Rajiv Kumar
Journal:  Clin Chem       Date:  2021-06-01       Impact factor: 8.327

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.